4/20
06:04 pm
srrk
Scholar Rock (SRRK) was given a new $62.00 price target by Canaccord Genuity Group Inc..
Low
Report
Scholar Rock (SRRK) was given a new $62.00 price target by Canaccord Genuity Group Inc..
4/17
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/16
08:00 am
srrk
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
Low
Report
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
4/6
08:26 am
srrk
Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal? [Yahoo! Finance]
Medium
Report
Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal? [Yahoo! Finance]
4/1
08:41 am
srrk
Scholar Rock (SRRK) had its price target raised by Wedbush from $56.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Scholar Rock (SRRK) had its price target raised by Wedbush from $56.00 to $58.00. They now have an "outperform" rating on the stock.
4/1
12:11 am
srrk
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept. [Yahoo! Finance]
Low
Report
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept. [Yahoo! Finance]
3/31
02:24 pm
srrk
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript [Seeking Alpha]
Low
Report
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript [Seeking Alpha]
3/31
07:00 am
srrk
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
High
Report
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
3/29
06:45 pm
srrk
A Look At Scholar Rock Holding (SRRK) Valuation As Growth Expectations Face Mixed Share Price Signals [Yahoo! Finance]
Low
Report
A Look At Scholar Rock Holding (SRRK) Valuation As Growth Expectations Face Mixed Share Price Signals [Yahoo! Finance]
3/28
10:26 am
srrk
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating [Seeking Alpha]
Low
Report
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating [Seeking Alpha]
3/16
02:52 pm
srrk
Scholar Rock (SRRK) had its price target raised by JPMorgan Chase & Co. from $47.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Scholar Rock (SRRK) had its price target raised by JPMorgan Chase & Co. from $47.00 to $50.00. They now have an "overweight" rating on the stock.
3/13
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/12
11:57 am
srrk
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/4
01:39 pm
srrk
Scholar Rock (SRRK) had its price target raised by Citigroup Inc. from $55.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Scholar Rock (SRRK) had its price target raised by Citigroup Inc. from $55.00 to $58.00. They now have a "buy" rating on the stock.
3/4
01:10 pm
srrk
Scholar Rock (SRRK) had its price target raised by BMO Capital Markets from $50.00 to $70.00. They now have an "outperform" rating on the stock.
Medium
Report
Scholar Rock (SRRK) had its price target raised by BMO Capital Markets from $50.00 to $70.00. They now have an "outperform" rating on the stock.
3/4
09:04 am
srrk
Scholar Rock (SRRK) had its price target raised by Piper Sandler from $51.00 to $58.00. They now have an "overweight" rating on the stock.
Medium
Report
Scholar Rock (SRRK) had its price target raised by Piper Sandler from $51.00 to $58.00. They now have an "overweight" rating on the stock.
3/3
06:06 pm
srrk
Scholar Rock (SRRK) had its "overweight" rating reaffirmed by Barclays PLC.
Medium
Report
Scholar Rock (SRRK) had its "overweight" rating reaffirmed by Barclays PLC.
3/3
05:02 pm
srrk
Scholar Rock (SRRK) was given a new $55.00 price target by Truist Financial Corporation.
Medium
Report
Scholar Rock (SRRK) was given a new $55.00 price target by Truist Financial Corporation.
3/3
04:47 pm
srrk
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/3
04:46 pm
srrk
Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress [Seeking Alpha]
Medium
Report
Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress [Seeking Alpha]
3/3
04:11 pm
srrk
Scholar Rock (SRRK) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..
Medium
Report
Scholar Rock (SRRK) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..
3/3
11:46 am
srrk
Scholar Rock (SRRK) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.
Medium
Report
Scholar Rock (SRRK) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.
3/3
07:00 am
srrk
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2/18
08:13 am
srrk
Scholar Rock to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Scholar Rock to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/18
08:00 am
srrk
Scholar Rock to Present at Upcoming Investor Conferences
Low
Report
Scholar Rock to Present at Upcoming Investor Conferences